IRIS PubliCatt

Evoli Stampanoni-B, Amelia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.382
EU - Europa 3.671
AS - Asia 1.488
SA - Sud America 61
AF - Africa 46
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 10
Totale 9.673
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.333
DE - Germania 1.040
CN - Cina 723
SE - Svezia 708
UA - Ucraina 417
IT - Italia 380
SG - Singapore 364
IE - Irlanda 225
FR - Francia 212
PL - Polonia 166
GB - Regno Unito 153
ID - Indonesia 133
FI - Finlandia 111
IN - India 104
RU - Federazione Russa 97
TR - Turchia 55
BE - Belgio 44
JP - Giappone 34
CI - Costa d'Avorio 32
NL - Olanda 26
RO - Romania 22
CA - Canada 21
ES - Italia 19
CL - Cile 17
EC - Ecuador 16
HK - Hong Kong 16
MX - Messico 15
AU - Australia 13
BR - Brasile 13
IL - Israele 13
CH - Svizzera 11
PE - Perù 8
CZ - Repubblica Ceca 7
IR - Iran 7
BZ - Belize 6
KE - Kenya 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BG - Bulgaria 5
GR - Grecia 5
KR - Corea 5
VN - Vietnam 5
EU - Europa 4
LK - Sri Lanka 4
PR - Porto Rico 4
TH - Thailandia 4
AZ - Azerbaigian 3
CO - Colombia 3
HU - Ungheria 3
IQ - Iraq 3
LT - Lituania 3
PT - Portogallo 3
AR - Argentina 2
AT - Austria 2
GA - Gabon 2
JO - Giordania 2
LU - Lussemburgo 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
OM - Oman 2
PH - Filippine 2
PK - Pakistan 2
SA - Arabia Saudita 2
A1 - Anonimo 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BF - Burkina Faso 1
CU - Cuba 1
DK - Danimarca 1
DZ - Algeria 1
KZ - Kazakistan 1
LV - Lettonia 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
NO - Norvegia 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
UY - Uruguay 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 9.673
Salva come PNG Salva come JPEG
Città #
Chandler 891
Ashburn 399
Jacksonville 281
Singapore 281
San Mateo 230
Dublin 216
Wilmington 155
Ann Arbor 154
Warsaw 143
Nanjing 141
Jakarta 133
Houston 118
Dearborn 116
Woodbridge 114
New York 98
Cattolica 96
Boston 95
Princeton 71
Redwood City 69
Beijing 66
Milan 63
Lawrence 61
Moscow 59
Chicago 53
Nürnberg 53
Fairfield 49
Marseille 49
Seattle 47
Bremen 46
Nanchang 45
Izmir 44
Fuzhou 42
Brussels 38
Hangzhou 37
Redmond 37
Los Angeles 33
Abidjan 32
Shanghai 31
Mountain View 30
London 28
Shenyang 27
Tianjin 26
Norwalk 25
Rome 25
Boardman 24
Hebei 24
Zhengzhou 24
Changsha 23
Helsinki 19
Kunming 18
Leawood 16
Munich 16
Jiaxing 15
Millbury 15
Cambridge 14
University Park 14
Hong Kong 13
Pune 12
Falls Church 11
Frankfurt am Main 11
Guangzhou 11
Philadelphia 11
Washington 11
Berlin 10
Fremont 10
Dagenham 9
Málaga 9
Paris 9
San Jose 9
Tokyo 9
Bologna 8
Indiana 8
Kraków 8
Saint Louis 8
Amsterdam 7
Buffalo 7
Hefei 7
Lancaster 7
Lanzhou 7
Loja 7
Arlington Heights 6
Belize City 6
Iasi 6
Nairobi 6
New Delhi 6
Ningbo 6
San Francisco 6
Toronto 6
Zurich 6
Augusta 5
Cleja 5
Edinburgh 5
Edmonton 5
Falkenstein 5
Guayaquil 5
Jinan 5
Lima 5
Madrid 5
Mexico City 5
Ottawa 5
Totale 5.397
Salva come PNG Salva come JPEG
Nome #
Myasthenia gravis 208
International consensus guidance for management of myasthenia gravis: Executive summary 201
Single-centre 40-year results of redo operation for recurrent thymomas. 190
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 148
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. 144
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. 141
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy 137
Thymoma in patients with MG: characteristics and long-term outcome 135
When myasthenia gravis is not all. 135
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 132
Hypoglossal palsy and coeliac disease: an uncommon presentation for a common disease? 131
Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. 128
SFEMG: A piece in the diagnostic puzzle of myasthenia 127
T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients 122
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data 118
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 112
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 112
A b3 type-thymoma in a 7-year-old child with myasthenia gravis 111
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 108
Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. 105
Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis 105
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 104
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 103
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders 103
Anti-AChR-negative myasthenia gravis: clinical and immunological features 102
A Genome-wide Association Study of Myasthenia Gravis 102
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 102
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies 94
Determinants of cognitive impairment in elderly myasthenia gravis patients 91
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. 90
The difficulty in confirming clinical diagnosis of Myasthenia Gravis in a seronegative patient: a possible neurophysiological approach 90
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. 89
Multiple paraneoplastic diseases associated with thymoma. 88
Response to therapy in myasthenia gravis with anti-MuSK antibody 86
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases 85
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis 85
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis 85
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. 84
BAFF serum levels in myasthenia gravis: effects of therapy 83
Tumour necrosis factor beta gene polymorphisms in myasthenia gravis 83
Diagnostic features and subtyping of thymoma lymph node metastases 83
Management challenges in muscle-specific tyrosine kinase myasthenia gravis. 82
Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. 81
Prognostic grading after complete resection for thymic malignancies 81
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long term results in 180 patients. 80
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 80
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients 77
Guidelines for treatment of autoimmune neuromuscular transmission disorders. 76
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology 76
Comment on "Cutting edge: human CD4-CD8- thymocytes express FOXP3 in the absence of a TCR". 75
Clinical heterogeneity of seronegative myasthenia gravis 75
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 75
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 74
Myasthenia gravis with antibodies to MuSK: an update 74
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 74
Immunosuppressive therapies in myasthenia gravis 73
Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function 72
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 71
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 71
Spontaneous recovery from anti-NMDAR encephalitis 69
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 69
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients 69
Acquired myasthenia gravis in childhood. 68
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study 68
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. 68
Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America 67
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 67
Positive response to therapy in a patient with a seropositive paraneoplastic cerebellar degeneration and an endometrioid carcinoma of the vesicovaginal septum 65
EFNS/ENS Guidelines for the treatment of ocular myasthenia. 64
Antibody-phenotype correlation in stiff-person syndrome 63
Early-onset myasthenia gravis: clinical characteristics and response to therapy 63
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 63
Risk of cancer in patients with myasthenia gravis 62
A practical guide to the recognition and management of myasthenia gravis 62
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody 62
Myasthenia gravis during interferon alfa therapy 60
Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. 60
In sickness and in health: when myasthenia gravis is a conjugal matter 60
Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase 59
Familial autoimmune myasthenia gravis with different pathogenetic antibodies 59
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 59
Course and treatment of myasthenia gravis during pregnancy 58
An update on Thymectomy in Myasthenia Gravis 58
Minimal manifestation status and prednisone withdrawal in the MGTX trial 58
Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement 56
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis 56
Risk factors for tumor occurrence in patients with myasthenia gravis. 55
Myasthenia gravis and associated autoimmune diseases 55
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma 55
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. 55
Imatinib mesylate in thymic epithelial malignancies. 54
The tiles make a puzzle but the single tile is not the puzzle: The need for a global assessment of the patient 54
Thymoma recurrences in myasthenia gravis patients 53
MuSK autoantibodies in myasthenia gravis detected by cell based assay-A multinational study 52
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update 52
Benefit and danger from immunotherapy in myasthenia gravis 52
242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1–3 March 2019 52
Controversies in Ocular Myasthenia Gravis 52
IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset 51
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 49
Totale 8.482
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020675 0 0 0 0 0 86 161 39 80 62 142 105
2020/2021987 66 105 19 99 135 50 135 28 121 52 143 34
2021/20221.290 111 97 32 69 97 45 34 197 62 78 182 286
2022/20232.629 313 361 205 387 155 311 256 217 273 41 70 40
2023/20241.174 53 318 47 84 46 163 86 74 11 27 132 133
2024/2025613 54 90 181 60 171 57 0 0 0 0 0 0
Totale 9.838